Korea FDA Approves Roche's Herceptin For First-line Metastatic Gastric Cancer
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA approved Roche's targeted anti-cancer drug Herceptin (trastuzumab) for first-line treatment of HER2-positive metastatic gastric cancer, providing a targeted therapy for the most common and leading cancer in Korea
You may also be interested in...
Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa
SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries
GSK Tykerb Poised To Make Inroads Against Roche's Herceptin After Adding First-Line Indication
GlaxoSmithKline's orally available cancer drug Tykerb (lapatinib) is poised to make inroads against Roche's Herceptin (trastuzumab) in the fight against one of the more deadly manifestations of metastatic breast cancer in post-menopausal women
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News